



Biologics in psoriasis; a step towards individualized treatment

J.S. van Bezooijen

LITERATUUR

1. Gelfand JM, Weinstein R, Porter SB, Neimann AL, Berlin JA, Margolis DJ. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. *Arch Dermatol* 2005;141(12):1537-41.
2. Boehncke WH, Schon MP. Psoriasis. *Lancet* 2015;386(9997):983-94.
3. Kirkham BW, Kavanaugh A, Reich K. Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis. *Immunology* 2014;141(2):133-42.
4. Ward NL, Umetsu DT. A new player on the psoriasis block: IL-17A- and IL-22-producing innate lymphoid cells. *J Invest Dermatol* 2014;134(9):2305-7.
5. Benson JM, Sachs CW, Treacy G, et al. Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab. *Nat Biotechnol* 2011;29(7):615-24.
6. Gaspari AA, Tying S. New and emerging biologic therapies for moderate-to-severe plaque psoriasis: mechanistic rationales and recent clinical data for IL-17 and IL-23 inhibitors. *Dermatol Ther* 2015;28(4):179-93.
7. Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis—results of two phase 3 trials. *N Engl J Med* 2014;371(4):326-38.
8. Kopp T, Riedl E, Bangert C, et al. Clinical improvement in psoriasis with specific targeting of interleukin-23. *N Engl J Med* 2015;373(12):1122-6.
9. Reek JM van den, Kievit W, Gniadecki R, et al. Drug survival studies in dermatology: principles, purposes, and pitfalls. *J Invest Dermatol* 2015;135(7):e34.
10. Baker MP, Reynolds HM, Lumicisi B, Bryson CJ. Immunogenicity of protein therapeutics: The key causes, consequences and challenges. *Self Nonself* 2010;1(4):314-22.